Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	1-ranibizumab Monotherapy	183
Overall Study	STARTED	2-ranibizumab With Laser	180
Overall Study	STARTED	3-laser Monotherapy	92
Overall Study	Completed 6 Mos	1-ranibizumab Monotherapy	174
Overall Study	Completed 6 Mos	2-ranibizumab With Laser	170
Overall Study	Completed 6 Mos	3-laser Monotherapy	80
Overall Study	COMPLETED	1-ranibizumab Monotherapy	161
Overall Study	COMPLETED	2-ranibizumab With Laser	154
Overall Study	COMPLETED	3-laser Monotherapy	65
Overall Study	NOT COMPLETED	1-ranibizumab Monotherapy	22
Overall Study	NOT COMPLETED	2-ranibizumab With Laser	26
Overall Study	NOT COMPLETED	3-laser Monotherapy	27

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01599650/flow